Innovacell develops investigational cell therapies for fecal and urinary incontinence. Its lead program, ICEF15, uses patients' own muscle-derived cells and is being studied for urge fecal incontinence, alongside other candidates targeting different forms of incontinence.
Its Austrian subsidiary, Innovacell GmbH, provides cell-production and development capabilities, including processes for transporting biopsies and cell products across borders. The group combines clinical research with manufacturing-process development as it works toward regulatory approval and commercialization.
0
open positions at Innovacell
No live listings from Innovacell right now — browse all Tokyo software jobs instead.